The BCL11B Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the BCL11B gene. Generated via CRISPR/Cas9-mediated gene disruption, this product enables the investigation of BCL11B-dependent transcriptional regulation and its impact on cellular processes in a widely utilized epithelial carcinoma model. The polyclonal nature provides a heterogeneous pool of edited alleles, reflecting population-level gene knockout effects without the clonal selection typically associated with monoclonal knockout lines.
These cells are derived from the HeLa cell line, which originates from a human papillomavirus 18 (HPV18)-positive cervical adenocarcinoma. HeLa cells are aneuploid, immortalized epithelial cells that have been extensively employed in biomedical research for over seven decades. Their robust growth characteristics, ease of transfection, and well-characterized signaling networks make them a versatile platform for genetic perturbation studies, including CRISPR-based knockout screening and mechanistic interrogation of cancer-relevant pathways.
BCL11B encodes a C2H2 zinc-finger transcription factor that functions primarily as a transcriptional repressor. It exerts its repressive activity by binding to gene regulatory elements and recruiting the nucleosome remodeling and deacetylase (NuRD) complex, which includes CHD4 and HDAC1/2. BCL11B is activated downstream of Notch signaling via the NICD-RBPJ-MAML1 complex and is further regulated by upstream factors including TCF7, GATA3, and the RUNX family. IL-7 signaling through JAK1/JAK3 and STAT5 also modulates BCL11B expression. Key downstream targets repressed by BCL11B include ID2 and RUNX3, which are critical for T-cell lineage commitment. Beyond T-cell biology, BCL11B participates in neurogenesis, epidermal homeostasis, and Wnt/??-catenin crosstalk. Its disruption in HeLa cells may derepress target genes, altering proliferation and differentiation programs.
In the HeLa cervical carcinoma context, BCL11B knockout provides a valuable model to delineate the transcription factor??s function beyond lymphoid lineages. HeLa cells retain functional Notch and Wnt/??-catenin pathways, allowing studies of BCL11B??s role in these conserved signaling cascades. The aneuploid, HPV-transformed background offers a relevant setting to explore how BCL11B loss influences oncogenic signaling, chromatin architecture, and gene expression in epithelial cancers. This model may aid in identifying synthetic lethal interactions for therapeutic targeting.
Key applications include functional genomics and CRISPR-based synthetic lethality screens, transcriptome profiling by RNA-seq, and ChIP-qPCR for binding site analysis. This model is well-suited for drug target validation in T-cell leukemia and lymphoma, where BCL11B is frequently dysregulated. Standard phenotypic characterization can be performed via Western blotting, RT-qPCR, proliferation and colony formation assays, flow cytometry, and co-immunoprecipitation with NuRD complex members. For further information, please contact Ascent Research.
